As another poster has already commented…Lonza Singapore Tuas , has already passed the last 20 site inspections successfully. I believe I read that the Singapore facility has never failed an FDA inspection !
https://www.lonza.com/about-us/our-locations/tuas-singapore
I have also heard it is almost unheard of for a therapy where a manufacturing inspection is undertaken to not be approved. I am not aware, that even the Walkersville problems of early 2017 led to any BLA rejections. I understand that even the delay referenced by Fiecepharma in the extremely rare, Liso-cel BMS example, amounted to about six months only, as it was granted FDA approval on the 2nd May 2021. Talk about clutching at straws. The only other occasion where I can find any real issues with a Lonza plant, dates is back to 2011, where production was subsequently moved from Hopkinton plant in Massachusetts to Visp Switzerland. The latter plant has a stellar safety record.
To show how certain posters are now clutching at straws, I reference the 33 successful inspections undertaken in 2021
https://www.lonza.com/annualreport/2021/documents/Lonza_2021_Sustainability_Report.pdf
Page 20 of the 2021 Sustainability Report
“In 2021 our sites underwent 33 regulatory inspections. In line with the increase of the commercial and development production, and a growing portfolio, the number of customer audits (on-site plus remote audits) also continues to increase. The successful inspections and audits are a valuable feedback loop to assure compliance across the company”
So after two successful mock internal and external audits of their Lonza Singapore facilty last year, Mesoblast must be feeling cock a hoop at the confirmation of the FDA site visit , which appears to be one of the last important milestone to be completed prior to an approval decision.
In my opinion, the application is 95% likely to succeed now….that is up from my previous expectation…and only a little higher than the William Blair analyst who has opined on the COS in his recent note !
Great news folks. Let’s wait to get past the Day 74 letter for the penny to drop this looks a winner. The institutions are being served up this opportunity on a plate. In my view today’s announcement substantially derisks the successful approval of this therapy. The shorters are trying to knock the price down to increase dilution and buy their stock back in a capital raising. What else can they do ? They have been successful so far in their manipulation of the stock price. History has shown, however, that most share prices run up materially ahead of a successful BLA application…with the current short position at 6%..they may have limited stock lending available to them….without a imminent capital raise they look terribly exposed…but they will not doubt defend their position. If one decent size long fund starts a holding in this Company , the shorters should be toast ! OP
Please do not rely on the accuracy of any facts or opinions expressed in the post above when making a financial decision .
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection, page-122
-
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.46 |
Change
0.088(6.36%) |
Mkt cap ! $1.644B |
Open | High | Low | Value | Volume |
$1.40 | $1.49 | $1.38 | $6.753M | 4.716M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 23364 | $1.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.47 | 15180 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 48210 | 1.465 |
8 | 24567 | 1.460 |
7 | 45701 | 1.455 |
7 | 74110 | 1.450 |
5 | 104649 | 1.445 |
Price($) | Vol. | No. |
---|---|---|
1.470 | 1876 | 5 |
1.475 | 17781 | 6 |
1.480 | 79882 | 11 |
1.485 | 114098 | 9 |
1.490 | 183584 | 10 |
Last trade - 15.33pm 17/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online